For clinical validation, while we confirmed elevated expression of SPANXB1 and its downstream effectors (YY1, H3R17me2, MMP1) in both primary breast tumors and brain metastases, the small sample size (n = 5 per group) necessitates validation in larger clinical cohorts. Here, YY1 is linked to breast neoplasm.